Is somatic testing usually ordered for prostate cancer

Excellent question - this reflects an important paradigm shift happening in prostate cancer management. The answer is increasingly YES, but adoption is still evolving.

Current Landscape: Somatic NGS in Prostate Cancer

Historical Context:

• 5-10 years ago: Somatic tumor sequencing was rarely ordered for prostate cancer

  • Viewed as having limited actionable targets
  • Reserved for castration-resistant disease (mCRPC) only
  • Not standard of care

• Current era (2020-2024): Rapidly expanding indications

  • Multiple FDA approvals for biomarker-directed therapies
  • NCCN guidelines now recommend testing
  • Still underutilized in community practice vs. academic centers

---

NCCN Guidelines: When to Order Somatic Testing

Category 1 Recommendation (Highest Evidence):

Metastatic Castration-Resistant Prostate Cancer (mCRPC):

• All patients with mCRPC should have somatic tumor testing
• Genes to test: HRR pathway genes (BRCA1/2, ATM, PALB2, CHEK2, CDK12, etc.), MSI/dMMR, TMB
• Rationale: FDA-approved therapies available based on biomarkers

Category 2A Recommendation (Strong Consensus):

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC):

• Somatic testing should be considered at diagnosis
• Rationale:
  • Identifies patients who may progress rapidly
  • Informs prognosis and treatment intensity
  • Prepares for future treatment decisions

Regional/High-Risk Localized Disease:

• Somatic testing may be considered (Category 2B - less consensus)
• Your father's case (cT2aN1M0) falls into this category
• Rationale:
  • HRR mutations predict more aggressive disease
  • May influence treatment intensification decisions
  • Identifies patients who need closer surveillance

---

FDA-Approved Biomarker-Directed Therapies in Prostate Cancer

1. PARP Inhibitors (HRR Mutations)

Olaparib (Lynparza):

• FDA approval: mCRPC with BRCA1/2 or ATM mutations (germline or somatic)
• PROfound trial: Olaparib vs. enzalutamide/abiraterone in HRR-mutated mCRPC
  • BRCA1/2 subgroup: Median rPFS 7.4 vs. 3.6 months (HR 0.34, p<0.001)
  • Overall HRR cohort: HR 0.49 for rPFS
• Indication: After progression on AR-targeted therapy (enzalutamide/abiraterone)

Rucaparib (Rubraca):

• FDA approval: mCRPC with BRCA1/2 mutation (germline or somatic)
• TRITON2 trial: ORR 44% in BRCA1/2-mutated mCRPC
• Indication: After AR-targeted therapy and taxane chemotherapy

Niraparib + Abiraterone (Akeega):

• FDA approval: mCRPC with BRCA1/2 mutation (germline or somatic)
• MAGNITUDE trial: Niraparib/abiraterone vs. placebo/abiraterone in HRR-mutated mCRPC
  • BRCA subgroup: Median rPFS 16.6 vs. 10.9 months (HR 0.53)
• Indication: First-line treatment for mCRPC (can be used earlier than olaparib/rucaparib)

Key point: ~20-25% of mCRPC patients have HRR mutations (12% germline, 8-13% somatic-only)

2. Immune Checkpoint Inhibitors (MSI-H/dMMR or TMB-High)

Pembrolizumab (Keytruda):

• FDA approval: Any solid tumor with MSI-H/dMMR or TMB-H (≥10 mut/Mb)
• Prostate cancer prevalence:
  • MSI-H/dMMR: 3-5% of prostate cancers (higher in mCRPC)
  • TMB-H: 3-7% of mCRPC
• KEYNOTE-158: ORR 34% in MSI-H solid tumors (including prostate)
• KEYNOTE-199: ORR 5% in unselected mCRPC (poor), but ~50% in MSI-H subset

Dostarlimab (Jemperli):

• FDA approval: dMMR solid tumors (tissue-agnostic)
• Alternative to pembrolizumab

3. Investigational/Emerging Targets

CDK12 mutations (~5-7% of mCRPC):

• Associated with tandem duplications and immunogenic phenotype
• May predict response to immune checkpoint inhibitors
• Clinical trials ongoing

PIK3CA/AKT1/PTEN alterations (~40% of mCRPC):

• PI3K/AKT pathway inhibitors in clinical trials
• Ipatasertib (AKT inhibitor) + abiraterone showed benefit in PTEN-loss patients (IPATential150 trial)

AR amplification/mutations (~50% of mCRPC):

• Predicts resistance to AR-targeted therapies
• May guide sequencing decisions

---

Prevalence of Actionable Somatic Alterations

Key Studies:

Robinson et al., Cell 2015 (SU2C/PCF Dream Team):

• 333 mCRPC patients with whole-exome sequencing
• Actionable alterations in 89% of patients:
  • HRR pathway: 19% (BRCA2 13%, ATM 7%, others)
  • PI3K pathway: 49% (PTEN loss, PIK3CA, AKT1)
  • AR pathway: 63% (amplification, mutations)
  • DNA repair: 23% total
  • MSI-H: 3%

Pritchard et al., NEJM 2016:

• 692 metastatic prostate cancer patients
• Germline mutations: 11.8% (BRCA2 5.3%, ATM 1.6%, CHEK2 1.9%)
• Somatic-only mutations: Additional 8-10%
• Total HRR alterations: ~20-25%

Abida et al., JCO 2019 (MSK-IMPACT):

• 1,033 mCRPC patients with targeted NGS (410 genes)
• Clinically actionable alterations:
  • HRR genes: 23%
  • MSI-H: 3%
  • TMB-H: 7%
  • Total with FDA-approved therapy: ~25-30%

---

Clinical Utility in Your Father's Case (Regional N1M0)

Arguments FOR Somatic Testing Now:

1. Prognostic Information:

• HRR mutations (especially BRCA2): Predict more aggressive disease, higher metastatic potential
  • May influence decision to treat equivocal nodes as N1
  • May favor treatment intensification (ADT + ARPI or docetaxel)

2. Treatment Planning:

• If BRCA2 or ATM mutation found: Plan for PARP inhibitor if progression to mCRPC
• If MSI-H/dMMR: Consider pembrolizumab if progression (rare but important)
• If CDK12 mutation: May predict immunotherapy response

3. Avoid Repeat Biopsy: